Coronado Industries Presents Clinical Data to European Health Commission.Business Editors and Health/Medical Writers FOUNTAIN HILLS, Ariz.--(BW HealthWire)--Feb. 9, 2000 Coronado Industries, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). , today announced that it will present five years' data collected through clinical trials of its patented Pneumatic Trabeculoplasty procedure (PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin (TM)) to the European Health Commission in Brussels, February 21, 22, 2000. The study results evidence the safety and efficacy of the PNT procedure, and will be presented to the Commission by Leo Leo, in astronomy Leo [Lat.,=the lion], northern constellation lying S of Ursa Major and on the ecliptic (apparent path of the sun through the heavens) between Cancer and Virgo; it is one of the constellations of the zodiac. Bores, M.D., the Medical Director of Coronado's wholly-owned subsidiary, Ophthalmic International. The Company's European National Health Care System consultant, Albert Reynolds, a former Prime Minister of Ireland, worked diligently with Brian Crawley, a member of the European Parliament Member of the European Parliament member n → Eurodéputé m , to arrange the presentation. Coronado President Gary Smith Gary Smith may refer to:
Smith continued, &uot;We are extremely grateful to Mr. Reynolds and Mr. Crawley for making our presentation to this prestigious gathering possible.&uot; Mr. Smith will accompany Dr. Bores to Brussels for the presentation. Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Opthalmic International, has developed and tested the patented procedure Pneumatic Trabeculoplasty (PNT(TM)), a non-invasive, highly-effective, and low-cost alternative to traditional treatments. Currently, the Company's pneumatic suction device and treatment are available throughout the European marketplace. Coronado awaits FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval, when it will license its patented treatment procedure and equipment in the United States. Forward-looking statements in this release are made pursuant to the &uot;safe harbor&uot; provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. For additional information, see www.coronadoindustries.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion